Investment Rating - The industry investment rating is "Outperform the Market" [3][44] Core Viewpoints - Supply chain logistics companies are leveraging their substantial transaction volumes to create a second growth curve through monetization of flow, extending their business from "logistics - trade - manufacturing" [5][18] - New business segments are experiencing high growth, with significant increases in profit margins. For instance, from 2018 to 2024, the annualized gross profit growth rate for Manufacturing at Wuchan Zhongda is 22%, while for Milky Way's distribution, it is 21% [6][19] - The potential for a "Davis Double" exists, where high growth in new business profits and rising profit shares could drive overall profit growth for companies, alongside a rebound in commodity prices and improved market sentiment [7][30] Summary by Sections 1.1 Transaction Volume and Growth - Supply chain companies handle substantial transaction volumes, but revenue growth in logistics or manufacturing is slowing, necessitating new growth points [10][12] - The revenue growth rates for various companies from 2018 to 2024 show a mix of positive and negative trends, indicating a need for strategic shifts [11] 1.2 Monetization Logic - The monetization logic follows a "logistics - trade - manufacturing" model, with companies like Wuchan Zhongda and Milky Way focusing on enhancing their manufacturing and distribution capabilities [13][15] 2.1 Flow Monetization and New Business Growth - Flow monetization is driving high growth in new business revenues and gross profits, with expectations for continued growth in the future [16][18] 2.2 Wuchan Zhongda: High Growth in Manufacturing - Wuchan Zhongda's high-end manufacturing business has seen a 26% annualized revenue and gross profit growth from 2016 to 2024, with a 28% year-on-year gross profit increase in the first half of 2025 [21][23] 2.3 Profit Growth Center Rising - The rising share of gross profits from new business segments for companies like Wuchan Zhongda and Milky Way indicates an upward trend in overall profit growth [27][29] 3.1 Supply Chain Profit Recovery - Supply chain profit growth is correlated with commodity prices, which are currently at a historical low, suggesting potential for recovery as commodity prices rise [31][33] 3.2 Valuation Upside - Domestic supply chain companies' PE and PB ratios are approaching those of Japanese trading companies, with expectations for higher valuations due to faster projected profit growth from 2024 to 2027 [34][36]

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

中国经济网北京9月26日讯 密尔克卫(603713.SH)昨晚发布股东减持股份计划公告。公司于2025年9月25日分别收到陈 银河、李仁莉、北京君联茂林股权投资合伙企业（有限合伙）（以下简称"君联茂林"）发来的《关于密尔克卫智能供应链 服务集团股份有限公司的股份减持计划告知函》。 公司实际控制人、控股股东陈银河计划通过大宗交易、集中竞价交易方式减持公司股份数量不超过2,371,800股，即减 持不超过公司总股本的1.50%，自公告之日起15个交易日后的3个月内进行。其中，以大宗交易方式减持的股份数量不超过 1,581,200股，以集中竞价交易方式减持的股份数量不超过790,600股。 公司实际控制人、股东李仁莉计划通过大宗交易、集中竞价交易方式减持公司股份数量不超过2,371,800股，即减持不 超过公司总股本的1.50%，自公告之日起15个交易日后的3个月内进行。其中，以大宗交易方式减持的股份数量不超过 1,581,200股，以集中竞价交易方式减持的股份数量不超过790,600股。 公司股东君联茂林计划通过大宗交易、集中竞价交易方式减持公司股份数量不超过1,616,613股，即减持不超过公司总 股本的1.0 ...

中国经济网北京9月26日讯密尔克卫（603713）(603713.SH)昨晚发布股东减持股份计划公告。公司于2025年9月25日分别收 到陈银河、李仁莉、北京君联茂林股权投资合伙企业(有限合伙)(以下简称"君联茂林")发来的《关于密尔克卫智能供应链服 务集团股份有限公司的股份减持计划告知函》。 公司实际控制人、控股股东陈银河计划通过大宗交易、集中竞价交易方式减持公司股份数量不超过2,371,800股，即减持不 超过公司总股本的1.50%，自公告之日起15个交易日后的3个月内进行。其中，以大宗交易方式减持的股份数量不超过 1,581,200股，以集中竞价交易方式减持的股份数量不超过790,600股。 公司实际控制人、股东李仁莉计划通过大宗交易、集中竞价交易方式减持公司股份数量不超过2,371,800股，即减持不超过 公司总股本的1.50%，自公告之日起15个交易日后的3个月内进行。其中，以大宗交易方式减持的股份数量不超过1,581,200 股，以集中竞价交易方式减持的股份数量不超过790,600股。 据新浪财经，数据显示，陈银河最初持股4357.8万股，占总股本的28.58%。陈银河从2022年2月10日起，第 ...

Core Viewpoint - The company, Milkway Intelligent Supply Chain Service Group Co., Ltd., announces a share reduction plan involving its major shareholders, which may impact the stock's market performance and investor sentiment [1][2]. Shareholder Holdings - As of the announcement date, the actual controller and major shareholder, Mr. Chen Yinhai, holds 42,689,599 shares, accounting for 27.00% of the total share capital. Ms. Li Renli, another actual controller and shareholder, holds 21,065,409 shares, representing 13.32%. The shareholder Junlian Maolin holds 1,616,613 shares, approximately 1.02% of the total share capital [1]. Reduction Plan Details - Mr. Chen Yinhai plans to reduce his holdings by up to 2,371,800 shares, not exceeding 1.50% of the total share capital, through block trades and centralized bidding within three months after 15 trading days from the announcement. The reduction will consist of a maximum of 1,581,200 shares via block trades and 790,600 shares via centralized bidding [2]. - Ms. Li Renli also plans to reduce her holdings by the same amount and under similar conditions as Mr. Chen [2]. - Junlian Maolin intends to reduce its holdings by up to 1,616,613 shares, not exceeding 1.02% of the total share capital, with a maximum of 56,000 shares through block trades and 1,560,613 shares through centralized bidding [2]. Additional Information - The reduction plan is subject to adjustments if there are changes in the company's stock, such as stock splits or capital increases [3]. - The shareholders have made commitments regarding their shareholding and reduction intentions, ensuring compliance with relevant regulations and maintaining transparency [6][12].

Group 1 - The core point of the announcement is the share reduction plan by major shareholders of Milkway Intelligent Supply Chain Service Group Co., Ltd. [1] - The actual controller and controlling shareholder, Mr. Chen Yinhai, holds 42,689,599 shares, accounting for 27.00% of the total share capital [2] - Shareholder Ms. Li Renli holds 21,065,409 shares, representing 13.32% of the total share capital [2] - Shareholder Junlian Maolin holds 1,616,613 shares, approximately 1.02% of the total share capital [2] Group 2 - Mr. Chen Yinhai plans to reduce his holdings by up to 2,371,800 shares, not exceeding 1.50% of the total share capital, within three months after 15 trading days from the announcement [3] - Ms. Li Renli also plans to reduce her holdings by up to 2,371,800 shares, not exceeding 1.50% of the total share capital, within the same timeframe [3] - Junlian Maolin plans to reduce its holdings by up to 1,616,613 shares, not exceeding 1.02% of the total share capital, within three months after three trading days from the announcement [3] Group 3 - The reduction will be executed through block trades and centralized bidding, with specific limits on the number of shares for each method [3] - If the company's stock is suspended during the pre-disclosure period, the start time for the reduction will be postponed accordingly [4] - Any changes in share capital due to stock dividends or capital increases will lead to adjustments in the number of shares to be reduced [5] Group 4 - The major shareholders have made commitments regarding their shareholding and reduction intentions, including lock-up periods and conditions for future reductions [6][9][12] - Mr. Chen Yinhai's commitments include not transferring shares for 36 months post-IPO and limiting annual transfers to 25% of his holdings during his tenure as a director [7] - Ms. Li Renli and Junlian Maolin have similar commitments regarding their shareholdings and reduction plans, ensuring compliance with relevant regulations [10][13]

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

Core Viewpoint - On September 25, no A-share listed companies disclosed any increase in shareholding, while 16 companies announced share reductions, indicating a trend of shareholder divestment in the market [1]. Summary by Category Share Reduction Details - Hanghua Co. plans to reduce up to 4.24 million shares of repurchased stock to supplement working capital [2] - Weili Sealing's shareholders plan to reduce up to 1% of the company's shares [2] - Milkewei's actual controller and shareholders intend to collectively reduce up to 4.02% of the company's shares [2] - Zhichun Technology's controlling shareholder reduced 4.2678 million shares on September 25 [2] - Xinao Micro's senior management plans to reduce up to 0.0134% of the company's shares [2] - Quanfeng Technology's Hesheng Health Insurance reduced 57.1419 million shares from September 22 to September 24 [2] - Morning Light Biological's senior management Li Fengfei plans to reduce up to 140,000 shares [2] - Everbright Jiabao's Jiading Jianye and Jiading Keti plan to reduce up to 1% of their shares [2] - Shengshi Technology's employee stock ownership platform plans to reduce up to 3% of the company's shares [2] - Xingsen Technology's actual controller Qiu Xingya reduced a total of 9.9639 million shares from August 5 to September 22 [2] - Haizheng Materials' Sinopec Capital plans to reduce up to 2.0267 million shares, accounting for 1% of the total share capital [2] - Zhengzhong Design's controlling shareholder plans to reduce up to 3% of the company's shares [2] - Baiya Co.'s three shareholders plan to collectively reduce up to 2% of the company's shares [2] - Jialiqi's shareholders plan to collectively reduce up to 3% of the company's shares [2] - Defu Technology's shareholders plan to collectively reduce up to 0.13% of the company's shares [2] - Jinyinhe's shareholders plan to reduce up to 0.35% of the company's total share capital [2] Market Signal - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [1]

Group 1 - The core viewpoint of the article discusses the strategic restructuring plans of controlling shareholders of Shenma Co. and Pingmei Co. [1] - Shenma Co. and Pingmei Co. are undergoing significant changes in their corporate structure, indicating potential shifts in their operational strategies and market positioning [1] - The restructuring may lead to enhanced operational efficiency and better resource allocation within the companies [1] Group 2 - Fangyuan Co. has signed a technology export cooperation agreement with a Japanese company and a target company, indicating potential growth opportunities through international collaboration [5] - Milkway's actual controller and shareholders plan to reduce their holdings by no more than 4.02% of the company's shares, which may impact investor sentiment [5] - Longda Meishi's controlling shareholder has had 0.7% of their shares judicially frozen, which could affect the company's stock performance [5] - Qibin Group plans to repurchase shares worth between 100 million to 200 million yuan, reflecting confidence in the company's future [5]

Mergers and Acquisitions - Zhongman Petroleum plans to acquire 49% stake in Xinhuaxia Dubai from Xinhuaxia Cayman for a transaction amount of 563 million RMB (approximately 79.32 million USD) [1] - Gansu Energy Chemical intends to acquire 100% stake in Gansu Energy Coal Storage and Transportation Company from its related party for a price of 102 million RMB, which constitutes a related party transaction but does not qualify as a major asset restructuring [2] - Yicheng New Energy received notification from its controlling shareholder, China Pingmei Shenma Group, regarding a strategic restructuring initiated by the Henan provincial government for Henan Energy Group and China Pingmei Shenma Group [3] Shareholding Changes - Shengshi Technology's employee shareholding platforms plan to collectively reduce their holdings by up to 3% of the company's shares, amounting to a maximum of 7.84 million shares [4] - Milkway's actual controllers, Chen Yinhai and Li Renli, plan to reduce their holdings by up to 4.02% of the company's shares through block trades and centralized bidding, with a specific reduction of up to 1.5% and an additional shareholder planning to reduce by up to 1.02% [5] - Haizheng Biomaterials announces that Sinopec Capital intends to reduce its holdings by no more than 1% of the company's shares, equating to a maximum of 202,670 shares [6] - Jialiqi's shareholders, holding a combined 6.7824% stake, plan to reduce their holdings by up to 3%, which translates to a maximum of 248,930 shares [7]